Amlodipine Pharmacology and Clinical Considerations

Mechanism of Action and Pharmacological Effects

Amlodipine is a dihydropyridine calcium channel blocker with pronounced peripheral arterial dilatory effects, unlike non-dihydropyridine calcium channel blockers which have minimal effects on cardiac conduction, atrioventricular node function, and sinus node function, as noted by the American Heart Association 1, 2
The European Society of Cardiology guidelines suggest that amlodipine has minimal effects on cardiac conduction, atrioventricular node function, and sinus node function, making it a suitable option for patients with certain cardiovascular conditions 1, 2

The American College of Cardiology recommends that dihydropyridine calcium channel blockers, including amlodipine, are not used as routine treatment in patients with heart failure with reduced ejection fraction (HFrEF) due to their potential adverse effects 3, 4
The American Heart Association suggests that amlodipine may be considered for management of hypertension or ischemic heart disease in patients with heart failure as it is generally well-tolerated and had neutral effects on morbidity and mortality in large randomized controlled trials 5
Rapid-release, short-acting dihydropyridines must be avoided without concomitant beta-blockade due to increased adverse potential, though this is less of a concern with long-acting amlodipine, as recommended by the American College of Cardiology 1, 6

The American Heart Association recommends that in cases of amlodipine overdose, calcium administration, vasopressors, and high-dose insulin therapy may be required for severe toxicity 7

The American College of Cardiology suggests that amlodipine should not be used as routine treatment for heart failure with reduced ejection fraction (HFrEF), though it may be considered for concurrent hypertension or angina as it has neutral effects on mortality 8
The American College of Cardiology recommends monitoring closely for signs of worsening heart failure, including increased dyspnea, weight gain, or edema, in patients taking amlodipine 8
The American College of Cardiology advises against combining amlodipine with non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in heart failure patients, as these agents cause myocardial depression 8
The American Heart Association warns that NSAIDs should be avoided in patients taking amlodipine for hypertension, as they worsen blood pressure control and may precipitate heart failure 8